{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T04:14:44Z","timestamp":1784607284801,"version":"3.55.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.jinf.2017.08.013","type":"journal-article","created":{"date-parts":[[2017,9,2]],"date-time":"2017-09-02T02:31:11Z","timestamp":1504319471000},"page":"395-408","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Role of rifampin for the treatment of bacterial infections other than mycobacteriosis"],"prefix":"10.1016","volume":"75","author":[{"given":"Chun-Yuan","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chung-Hao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Po-Liang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Chien","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Hsu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7502-9225","authenticated-orcid":false,"given":"Po-Ren","family":"Hsueh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jinf.2017.08.013_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/599376","article-title":"Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America","volume":"49","author":"Mermel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0015","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0020","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cis803","article-title":"Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America","volume":"56","author":"Osmon","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jmii.2015.05.011","article-title":"Effects of various antimicrobial stewardship programs on antimicrobial usage and resistance among common gram-negative bacilli causing health care-associated infections: a multicenter comparison","volume":"49","author":"Lai","year":"2016","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0030","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0035","doi-asserted-by":"crossref","first-page":"S428","DOI":"10.1093\/clinids\/5.Supplement_3.S428","article-title":"Pharmacokinetics and metabolism of rifampin in humans","volume":"5","author":"Acocella","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0040","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1128\/CMR.00034-09","article-title":"Rifampin combination therapy for nonmycobacterial infections","volume":"23","author":"Forrest","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2017.08.013_bib0045","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/jac\/29.6.719","article-title":"Penetration of rifampicin into the cerebrospinal fluid of adults with uninflamed meninges","volume":"29","author":"Nau","year":"1992","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0050","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1128\/AAC.39.9.1988","article-title":"Bactericidal activity against cephalosporin-resistant Streptococcus pneumoniae in cerebrospinal fluid of children with acute bacterial meningitis","volume":"39","author":"Klugman","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0055","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2017.08.013_bib0060","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jfma.2012.05.012","article-title":"Epidemiology and staphylococcal cassette chromosome mec typing of methicillin-resistant Staphylococcus aureus isolates in Taiwan: a multicenter study","volume":"113","author":"Pan","year":"2014","journal-title":"J Formos Med Assoc"},{"key":"10.1016\/j.jinf.2017.08.013_bib0065","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cmi.2016.01.007","article-title":"ESCMID guideline: diagnosis and treatment of acute bacterial meningitis","volume":"22","author":"van de Beek","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0070","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1086\/425368","article-title":"Practice guidelines for the management of bacterial meningitis","volume":"39","author":"Tunkel","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijid.2013.09.012","article-title":"Mortality indicators in pneumococcal meningitis: therapeutic implications","volume":"19","author":"Erdem","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0080","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(12)61186-6","article-title":"Advances in treatment of bacterial meningitis","volume":"380","author":"van de Beek","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jinf.2017.08.013_bib0085","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00006454-200206000-00034","article-title":"Management of pneumococcal meningitis","volume":"21","author":"Kaplan","year":"2002","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jinf.2017.08.013_bib0090","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1111\/j.1365-2958.2010.07271.x","article-title":"Vancomycin tolerance in clinical and laboratory Streptococcus pneumoniae isolates depends on reduced enzyme activity of the major LytA autolysin or cooperation between CiaH histidine kinase and capsular polysaccharide","volume":"77","author":"Moscoso","year":"2010","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.jinf.2017.08.013_bib0095","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijantimicag.2005.06.010","article-title":"Rifampicin+ ceftriaxone vs. vancomycin+ ceftriaxone in the treatment of penicillin-and cephalosporin-resistant pneumococcal meningitis in an experimental rabbit model","volume":"26","author":"Suntur","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2017.08.013_bib0100","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1128\/AAC.39.9.2158","article-title":"Influence of dexamethasone on efficacy of ceftriaxone and vancomycin therapy in experimental pneumococcal meningitis","volume":"39","author":"Cabellos","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0105","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1128\/AAC.38.6.1320","article-title":"Effect of dexamethasone on therapy of experimental penicillin-and cephalosporin-resistant pneumococcal meningitis","volume":"38","author":"Paris","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0110","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.ijantimicag.2003.07.015","article-title":"Evaluation of a triple-drug combination for treatment of experimental multidrug-resistant pneumococcal meningitis","volume":"23","author":"Lee","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2017.08.013_bib0115","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0891-5520(05)70254-3","article-title":"Antibacterial agents in infections of the central nervous system","volume":"14","author":"Chowdhury","year":"2000","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.jinf.2017.08.013_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13054-015-1021-7","article-title":"Rifampin use in acute community-acquired meningitis in intensive care units: the French retrospective cohort ACAM-ICU study","volume":"19","author":"Bretonni\u00e8re","year":"2015","journal-title":"Crit Care"},{"key":"10.1016\/j.jinf.2017.08.013_bib0125","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1097\/MD.0b013e3181d5453d","article-title":"Staphylococcus aureus meningitis: case series and literature review","volume":"89","author":"Aguilar","year":"2010","journal-title":"Medicine"},{"key":"10.1016\/j.jinf.2017.08.013_bib0130","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.diagmicrobio.2011.07.001","article-title":"Combination therapy with daptomycin, linezolid, and rifampin as treatment option for MRSA meningitis and bacteraemia","volume":"71","author":"Kelesidis","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0135","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1086\/323021","article-title":"Emergence of rifampin-resistant Streptococcus pneumoniae as a result of antimicrobial therapy for penicillin-resistant strains","volume":"33","author":"van Tilburg","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0140","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/cix152","article-title":"2017 Infectious Diseases Society of America's clinical practice guidelines for healthcare-associated ventriculitis and meningitis","author":"Tunkel","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0145","doi-asserted-by":"crossref","first-page":"e1816","DOI":"10.1097\/MD.0000000000001816","article-title":"Current epidemiology and outcome of infective endocarditis: a multicenter, prospective, cohort study","volume":"94","author":"Mu\u00f1oz","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jinf.2017.08.013_bib0150","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s10096-016-2660-6","article-title":"The causative agents in infective endocarditis: a systematic review comprising 33,214 cases","volume":"35","author":"Vogkou","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0155","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jinf.2017.08.013_bib0160","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1093\/eurheartj\/ehv319","article-title":"2015 ESC guidelines for the management of infective endocarditis","volume":"36","author":"Habib","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jinf.2017.08.013_bib0165","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1128\/CMR.00134-14","article-title":"Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management","volume":"28","author":"Tong","year":"2015","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jinf.2017.08.013_bib0170","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jac\/dkr450","article-title":"Guidelines for the diagnosis and antibiotic treatment of endocarditis in adults: a report of the Working Party of the British Society for Antimicrobial Chemotherapy","volume":"67","author":"Gould","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0175","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1093\/infdis\/151.1.157","article-title":"Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in\u00a0vitro-in\u00a0vivo correlations","volume":"151","author":"Bayer","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0180","doi-asserted-by":"crossref","first-page":"674","DOI":"10.7326\/0003-4819-115-9-674","article-title":"Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis","volume":"115","author":"Levine","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jinf.2017.08.013_bib0185","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1128\/AAC.00300-08","article-title":"Addition of rifampin to standard therapy for treatment of native valve infective endocarditis caused by Staphylococcus aureus","volume":"52","author":"Riedel","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0190","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/j.athoracsur.2015.11.015","article-title":"Rifampin for surgically treated staphylococcal infective endocarditis: a propensity score-adjusted cohort study","volume":"101","author":"Shrestha","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jinf.2017.08.013_bib0195","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2013.05.005","article-title":"Daptomycin: the role of high-dose and combination therapy for gram-positive infections","volume":"42","author":"Gould","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2017.08.013_bib0200","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s15010-016-0874-2","article-title":"Should daptomycin\u2013rifampin combinations for MSSA\/MRSA isolates be avoided because of antagonism?","volume":"44","author":"Stein","year":"2016","journal-title":"Infection"},{"key":"10.1016\/j.jinf.2017.08.013_bib0205","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1128\/AAC.00325-12","article-title":"Relationship of in\u00a0vitro synergy and treatment outcome with daptomycin plus rifampin in patients with invasive methicillin-resistant Staphylococcus aureus infections","volume":"57","author":"Rose","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0210","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1128\/AAC.47.5.1714-1718.2003","article-title":"Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"47","author":"Sakoulas","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0215","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1128\/AAC.00051-09","article-title":"Addition of gentamicin or rifampin does not enhance the effectiveness of daptomycin in treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus","volume":"53","author":"Mir\u00f3","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0220","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1345\/aph.1M665","article-title":"Successful treatment of daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus bacteraemia with the addition of rifampin to daptomycin","volume":"44","author":"Ahmad","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0225","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/mdr.2010.0001","article-title":"Daptomycin and rifampin for the treatment of methicillin-resistant Staphylococcus aureus septic pulmonary emboli in the absence of endocarditis","volume":"16","author":"Gomez","year":"2010","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.jinf.2017.08.013_bib0230","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jinf.2010.07.014","article-title":"Community associated methicillin resistant Staphylococcus aureus (CA-MRSA) infective endocarditis in Italy","volume":"61","author":"Bassetti","year":"2010","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0235","series-title":"Presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria","article-title":"Adjunctive rifampicin to reduce early mortality from Staphylococcus aureus bacteraemia: final results from the multi-centre, randomised blinded placebocontrolled ARREST trial","author":"Thwaites","year":"2017"},{"key":"10.1016\/j.jinf.2017.08.013_bib0240","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1517\/13543784.2016.1168803","article-title":"Investigational drugs in phase I and phase II clinical trials for the treatment of hospital-acquired pneumonia","volume":"25","author":"Falco","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.jinf.2017.08.013_bib0245","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MCP.0b013e32835f27be","article-title":"Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management","volume":"19","author":"Barbier","year":"2013","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jinf.2017.08.013_bib0250","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/MCP.0000000000000151","article-title":"Ventilator associated pneumonia in the ICU: where has it gone?","volume":"21","author":"Guillamet","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jinf.2017.08.013_bib0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/CCM.0b013e3181b9ecea","article-title":"Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia","volume":"38","author":"Jung","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.08.013_bib0260","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/CCM.0b013e3181e4b623","article-title":"Vancomycin plus rifampicin for methicillin-resistant Staphylococcus aureus pneumonia benefits only those who have no development of rifampicin resistance during treatment","volume":"38","author":"Lim","year":"2010","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jinf.2017.08.013_bib0265","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1345\/aph.1R370","article-title":"Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia","volume":"46","author":"Segarra-Newnham","year":"2012","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0270","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1099\/jmm.0.000144","article-title":"Combined therapy for multi-drug-resistant Acinetobacter baumannii infection\u2013is there evidence outside the laboratory?","volume":"64","author":"Tuon","year":"2015","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jinf.2017.08.013_bib0275","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0280","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1055\/s-0034-1398388","article-title":"Acinetobacter baumannii: evolution of antimicrobial resistance-treatment options","volume":"36","author":"Doi","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.jinf.2017.08.013_bib0285","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/653120","article-title":"Treatment of Acinetobacter infections","volume":"51","author":"Fishbain","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0290","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1128\/AAC.04089-14","article-title":"In\u00a0vitro activities of combinations of rifampin with other antimicrobials against multidrug-resistant Acinetobacter baumannii","volume":"59","author":"Bai","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0295","doi-asserted-by":"crossref","first-page":"e0151270","DOI":"10.1371\/journal.pone.0151270","article-title":"Antimicrobial combinations against pan-resistant Acinetobacter baumannii isolates with different resistance mechanisms","volume":"11","author":"Leite","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.jinf.2017.08.013_bib0300","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1099\/jmm.0.036939-0","article-title":"In\u00a0vitro time-kill studies of antimicrobial agents against blood isolates of imipenem-resistant Acinetobacter baumannii, including colistin-or tigecycline-resistant isolates","volume":"61","author":"Peck","year":"2012","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jinf.2017.08.013_bib0305","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijantimicag.2007.07.007","article-title":"Comparative activities of colistin, rifampicin, imipenem and sulbactam\/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases","volume":"30","author":"Tripodi","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2017.08.013_bib0310","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1128\/AAC.00367-09","article-title":"Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii","volume":"54","author":"Pach\u00f3n-Ib\u00e1\u00f1ez","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0315","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10096-011-1173-6","article-title":"Efficacy of rifampin, in monotherapy and in combinations, in an experimental murine pneumonia model caused by panresistant Acinetobacter baumannii strains","volume":"30","author":"Pach\u00f3n-Ib\u00e1\u00f1ez","year":"2011","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0320","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/cid\/cit253","article-title":"Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii. A multicentre, randomised, clinical trial","volume":"57","author":"Durante-Mangoni","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0325","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1017\/S095026881200194X","article-title":"Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia","volume":"141","author":"Aydemir","year":"2013","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0330","doi-asserted-by":"crossref","first-page":"448","DOI":"10.4103\/0255-0857.103767","article-title":"Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy?","volume":"30","author":"Simsek","year":"2012","journal-title":"Indian J Med Microbiol"},{"key":"10.1016\/j.jinf.2017.08.013_bib0335","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1099\/jmm.0.029439-0","article-title":"Clinical and microbiological characterization of carbapenem-resistant Acinetobacter baumannii bloodstream infections","volume":"60","author":"Song","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.jinf.2017.08.013_bib0340","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ijantimicag.2008.04.013","article-title":"Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii","volume":"32","author":"Song","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2017.08.013_bib0345","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/jac\/dkm509","article-title":"Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections","volume":"61","author":"Bassetti","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0350","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/dkl274","article-title":"Rifampicin\/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections","volume":"58","author":"Saballs","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0355","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/j.1469-0691.2005.01198.x","article-title":"Combined colistin and rifampicin therapy for carbapenem-resistant Acinetobacter baumannii infections: clinical outcome and adverse events","volume":"11","author":"Petrosillo","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0360","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jinf.2005.11.019","article-title":"Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii","volume":"53","author":"Motaouakkil","year":"2006","journal-title":"J Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0365","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.diagmicrobio.2015.09.012","article-title":"Mature biofilms of Enterococcus faecalis and Enterococcus faecium are highly resistant to antibiotics","volume":"84","author":"Holmberg","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0370","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.pharmthera.2016.02.006","article-title":"New frontiers for anti-biofilm drug development","volume":"160","author":"Ribeiro","year":"2016","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.jinf.2017.08.013_bib0375","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1128\/AAC.50.1.55-61.2006","article-title":"Multiple combination bactericidal testing of staphylococcal biofilms from implant-associated infections","volume":"50","author":"Saginur","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0380","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jse.2012.01.006","article-title":"Periprosthetic infections after total shoulder arthroplasty: a 33-year perspective","volume":"21","author":"Singh","year":"2012","journal-title":"J Shoulder Elb Surg"},{"key":"10.1016\/j.jinf.2017.08.013_bib0385","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11999-009-1013-5","article-title":"Prosthetic joint infection risk after TKA in the Medicare population","volume":"468","author":"Kurtz","year":"2010","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.jinf.2017.08.013_bib0390","doi-asserted-by":"crossref","first-page":"923","DOI":"10.5301\/ijao.5000168","article-title":"Epidemiology and new developments in the diagnosis of prosthetic joint infection","volume":"35","author":"Corvec","year":"2012","journal-title":"Int J Artif Organs"},{"key":"10.1016\/j.jinf.2017.08.013_bib0395","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.jmii.2013.08.007","article-title":"Clinical characteristics, microbiology, and outcomes of prosthetic joint infection in Taiwan","volume":"48","author":"Tsai","year":"2015","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0400","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s00264-015-2819-2","article-title":"Predictors of treatment outcome in prosthetic joint infections treated with prosthesis retention","volume":"39","author":"Puhto","year":"2015","journal-title":"Int Orthop"},{"key":"10.1016\/j.jinf.2017.08.013_bib0405","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/cir402","article-title":"Outcome and predictors of treatment failure in total hip\/knee prosthetic joint infections due to Staphylococcus aureus","volume":"53","author":"Senneville","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0410","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1001\/jama.279.19.1537","article-title":"Role of rifampin for treatment of orthopedic implant\u2013related staphylococcal infections: a randomized controlled trial","volume":"279","author":"Zimmerli","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jinf.2017.08.013_bib0415","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1093\/jac\/dkp107","article-title":"One hundred and twelve infected arthroplasties treated with \u2018DAIR\u2019 (debridement, antibiotics and implant retention): antibiotic duration and outcome","volume":"63","author":"Byren","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0420","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10096-010-0952-9","article-title":"Efficacy and safety of rifampin containing regimen for staphylococcal prosthetic joint infections treated with debridement and retention","volume":"29","author":"El Helou","year":"2010","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0425","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/cid\/cis746","article-title":"A large multicenter study of methicillin\u2013susceptible and methicillin\u2013resistant Staphylococcus aureus prosthetic joint infections managed with implant retention","volume":"56","author":"Lora-Tamayo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0430","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.medmal.2015.11.007","article-title":"Predictors of failure for prosthetic joint infections treated with debridement","volume":"46","author":"Letouvet","year":"2016","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.jinf.2017.08.013_bib0435","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1128\/AAC.00675-11","article-title":"Adjunctive rifampin is crucial to optimizing daptomycin efficacy against rabbit prosthetic joint infection due to methicillin-resistant Staphylococcus aureus","volume":"55","author":"Saleh-Mghir","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0440","doi-asserted-by":"crossref","first-page":"5251","DOI":"10.1128\/AAC.00226-10","article-title":"Efficacy of usual and high doses of daptomycin in combination with rifampin vs. alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus","volume":"54","author":"Garrigos","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0445","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2015.04.004","article-title":"Daptomycin combinations as alternative therapies in experimental foreign-body infection caused by methicillin-susceptible Staphylococcus aureus","volume":"46","author":"El Haj","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jinf.2017.08.013_bib0450","doi-asserted-by":"crossref","first-page":"3505","DOI":"10.1128\/AAC.01728-08","article-title":"Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm","volume":"53","author":"Stewart","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0455","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.diagmicrobio.2014.05.022","article-title":"High doses of daptomycin (10\u00a0mg\/kg\/d) plus rifampin for the treatment of staphylococcal prosthetic joint infection managed with implant retention: a comparative study","volume":"80","author":"Lora-Tamayo","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0460","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.sder.2005.03.001","article-title":"Insights in the pathogenic potential of Propionibacterium acnes from its complete genome","volume":"24","author":"Br\u00fcggemann","year":"2005","journal-title":"Semin Cutan Med Surg"},{"key":"10.1016\/j.jinf.2017.08.013_bib0465","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1128\/AAC.05552-11","article-title":"Role of rifampin against Propionibacterium acnes biofilm in\u00a0vitro and in an experimental foreign-body infection model","volume":"56","author":"Tafin","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jinf.2017.08.013_bib0470","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jse.2012.07.007","article-title":"Propionibacterium acnes: an underestimated aetiology in the pathogenesis of osteoarthritis?","volume":"22","author":"Levy","year":"2013","journal-title":"J Shoulder Elb Surg"},{"key":"10.1016\/j.jinf.2017.08.013_bib0475","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1086\/588477","article-title":"Propionibacterium acnes postoperative shoulder arthritis: an emerging clinical entity","volume":"46","author":"Levy","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0480","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/17453674.2015.1094613","article-title":"Treatment of prosthetic joint infections due to Propionibacterium: similar results in 60 patients treated with and without rifampicin","volume":"87","author":"Jacobs","year":"2015","journal-title":"Acta Orthop"},{"key":"10.1016\/j.jinf.2017.08.013_bib0485","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv191","article-title":"Characteristics and treatment outcomes of Propionibacterium acnes prosthetic shoulder infections in adults","volume":"3","author":"Piggott","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jinf.2017.08.013_bib0490","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.anaerobe.2015.05.003","article-title":"Occurrence and new mutations involved in rifampicin-resistant Propionibacterium acnes strains isolated from biofilm or device-related infections","volume":"34","author":"Tafin","year":"2015","journal-title":"Anaerobe"},{"key":"10.1016\/j.jinf.2017.08.013_bib0495","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0092-8674(01)00286-0","article-title":"Structural mechanism for rifampicin inhibition of bacterial RNA polymerase","volume":"104","author":"Campbell","year":"2001","journal-title":"Cell"},{"key":"10.1016\/j.jinf.2017.08.013_bib0500","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1532-5415.2010.02842.x","article-title":"Emergence of rifampicin resistance during rifampicin-containing treatment in elderly patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia","volume":"58","author":"Lai","year":"2010","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jinf.2017.08.013_bib0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317302712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445317302712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T21:25:18Z","timestamp":1759008318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445317302712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0163445317302712"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2017.08.013","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of rifampin for the treatment of bacterial infections other than mycobacteriosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2017.08.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The British Infection Association. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}